We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Comprehensive Genomic Testing Reveals Treatment Targets In 90% Of Advanced Solid Tumors

By LabMedica International staff writers
Posted on 31 Jul 2025

Patients with advanced solid tumors often face limited treatment options, in part because conventional testing methods fail to detect many of the genetic mutations that could guide targeted therapies. More...

Many significant alterations occur at low levels and may be missed by simpler diagnostics, leading to missed opportunities for personalized care. Additionally, standard DNA testing can overlook gene fusions—unusual genetic events that can drive cancer growth—leaving clinicians without crucial information to inform therapy planning. The need for comprehensive, sensitive, and inclusive molecular testing is critical in ensuring that subtle but therapeutically relevant mutations are identified. Now, a new study has revealed that over 90% of tumor samples contained genetic changes that could help guide treatment decisions, offering new hope for personalized cancer care.

The study, led by Exact Sciences (Madison, WI, USA), utilized the company’s OncoExTra assay to analyze over 10,000 advanced solid tumor samples. The research covered 31 types of cancers, including breast, prostate, colorectal, lung, and ovarian. The OncoExTra assay integrates both DNA and RNA sequencing to provide a full molecular profile of each tumor. This dual approach is particularly valuable in detecting gene fusions and other events that may not be apparent through DNA sequencing alone. According to the findings, published in Oncotarget, 29.2% of samples had biomarkers linked to on-label treatments, while 28.0% were associated with off-label therapies.

Additionally, 7.5% of samples contained gene fusions, reinforcing the importance of including RNA sequencing in molecular diagnostics, which helped identify high rates of gene fusions in prostate cancer and certain sarcomas. The results validate the assay’s ability to detect a wide range of clinically relevant genomic alterations, including rare or low-level mutations and fusion events. By identifying these genetic events, the test paves the way for precision therapies and improved patient outcomes. This advanced testing method reveals treatment opportunities even in advanced cancers, potentially guiding more personalized cancer care in real-world clinical settings.

Related Links:
Exact Sciences


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
New
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: Automated cell imaging discriminates CD8+ T cells according to natalizumab treatment outcome in MS patients (B Chaves et al., Nat Commun 16, 5533 (2025). DOI: 10.1038/s41467-025-60224-3)

Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients

Multiple sclerosis (MS) is a chronic autoimmune and degenerative neurological disease that affects the central nervous system, leading to motor, cognitive, and mental impairments. Symptoms can include... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.